Breaking News

Cytovance Manufactures ARMO’s Lead Candidate

June 23, 2014

Provides drug product for Phase I trials

Cytovance Biologics has completed GMP manufacture of ARMO BioSciences’ lead product, AM0010, a PEGylated form of recombinant human interleukin-10 (PEG-IL-10) being studied in advanced solid tumors.
 
“Cytovance is proud to have been an integral partner in the manufacture of AM0010 bulk drug substance and drug product,” said Darren Head, president and chief executive officer of Cytovance Biologics. “Our team responded to the urgency to get this important drug to patients with advanced solid tumors.”
 
“Cytovance’s responsive and professional team enabled us to accelerate the time to clinic of AM0010 which is currently in a Phase I dose escalation study in patients with cancer,” said Peter Van Vlasselaer, Ph.D., president and chief executive officer of ARMO. “We look forward to continuing our relationship with Cytovance as the manufacturer of product in support of the clinical development of AM0010.”

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks